左西孟旦联合托伐普坦治疗急性心力衰竭的效果分析

Analysis of the effect of levosimendan combined with tolvaptan in the treatment of acute heart failure

目的研究左西孟旦联合托伐普坦治疗急性心力衰竭的临床效果。方法选取2018年2月至2019年2月在本院进行治疗的80例急性心力衰竭患者,按照随机数字表法分为实验组和参照组,各40例。参照组应用常规的方式予以治疗,实验组患者则接受左西孟旦联合托伐普坦进行治疗,对两组患者的治疗疗效,治疗前后的收缩压、心率、左心室射血分数、脑钠肽、24 h尿量等临床数据进行对比。结果实验组患者的治疗疗效明显优于参照组,差异具有统计学意义(P<0.05);治疗前实验组的收缩压、心率、左心室射血分数、脑钠肽和24 h尿量分别为(154.82±17.15)mmHg、(112.33±19.84)bpm、(38.96±7.75)%、(3 098.84±1270.8)pg/mL、(813.6±214.32)mL,参照组患者为(151.46±17.34)mmHg、(109.35±22.47)bpm、(40.35±6.72)%、(2 898.35±1 260.4)pg/mL、(824.9±224.33)mL,两组比较差异无统计学意义;治疗后,实验组患者分别为(121.68±7.35)mmHg、(79.68±11.96)bpm、(52.37±6.03)%、(354.26±127.8)pg/mL、(2014.15±329.18)mL,参照组分别为(138.26±12.57)mmHg、(94.87±20.37)bpm、(44.32±6.17)%、(1 289.71±468.9)pg/mL、(1 088.42±225.39)mL,实验组患者各指标显著优于参照组,差异具有统计学意义(P<0.05)。结论应用左西孟旦与托伐普坦联合的方式对急性心力衰竭患者进行治疗,能够显著改善患者的临床相关症状以及治疗疗效,具有显著的应用价值,值得临床广泛应用。

Objective To study the clinical effect of levosimendan combined with tolvaptan in the treatment of acute heart failure. Methods 80 patients with acute heart failure who were treated in our hospital from February 2018 to February 2019 were enrolled in the study. All patients were divided into the experimental group and the reference group according to the random number table method, with 40 cases in each group. The reference group was treated with conventional manner. The experimental group received levosimendan combined with tolvaptan. The therapeutic effect on the two groups of patients, clinical data such as systolic blood pressure before and after treatment, heart rate, left ventricular ejection fraction, brain sodium peptide and 24 h urine volume were compared. Results The therapeutic effect of the experimental group was significantly better than that of the reference group. The difference before and after treatment was statistically significant(P<0.05). The systolic blood pressure, heart rate, left ventricular ejection fraction, brain natriuretic peptide and 24 h urine output data of the experimental group before treatment were respectively(154.82±17.15)mmHg,(112.33±19.84) bpm,(38.96±7.75)%,(3 098.84±1270.8) pg/mL,(813.6±214.32) mL, and the data of the reference group were(151.46±17.34) mmHg,(109.35±22.47) bpm,(40.35±6.72)%,(2 898.35±1260.4) pg/mL,(824.9±224.33) mL, there was no significantly difference between two groups. After treatment, the clinical data of the two groups were obvious improvement, the experimental group data were(121.68±7.35) mmHg,(79.68±11.96) bpm,(52.37±6.03)%,(354.26±127.8) pg/mL,(2 014.15±329.18) mL, the reference group patient data was(138.26±12.57) mmHg,(94.87±20.37) bpm,(44.32±6.17)%,(1 289.71±468.9) pg/mL,(1 088.42±225.39) mL, the experimental group data was significantly better than the reference group, the difference was statistically significant(P<0.05). Conclusion The combination of levosimendan and tolvaptan in the treatment of patients with acute heart failure can significantly improve the clinical symptoms and therapeutic effects of patients. Therefore, this kind of treatment has significant application value and is worthy of clinical extensiveness application.